Clinical trial
Understanding the Outcomes and Rationale for Treatment Decisions in Patients With Intermediate and High-risk Nonmuscle Invasive Bladder Cancer and Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer: A Multi-center Prospective Observational Trial.
NCT07893509 is registered in ClinicalTrials.gov with Bladder Cancer Advocacy Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Understanding the Outcomes and Rationale for Treatment Decisions in Patients With Intermediate and High-risk Nonmuscle Invasive Bladder Cancer and Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer: A Multi-center Prospective Observational Trial.
- Lead sponsor
- Bladder Cancer Advocacy Network
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- March 31, 2027
- Completion date
- May 31, 2032
- Enrollment
- 1,400 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
mibc, muscle invasive bladder cancer (mibc), nmibc, non muscle invasive bladder cancer
Arms
As registered; 5 arms.
-
Arm I: IR NMIBC
Patients with Intermediate Risk non-muscle invasive bladder cancer
-
Arm II: HR BCG naïve NMIBC
Non-Muscle I invasive Bladder Cancer who have never received BCG, or patients who had a complete response to BCG and relapsed more than 24 months after their last BCG dose.
-
Arm Ill: HR BCG exposed NMIBC
Includes:
* BCG-resistant NMIBC: Persistent or recurrent high-grade Ta or CIS disease at 3mo evaluation after at least 5/6 doses induction BCG.
* Delayed relapse after inadequate BCG: Although maintenance BCG should always follow successful induction BCG according to the guidelines, many patients only receive induction without maintenance. Disease-free at the 3mo evaluation, so the earliest relapse would be 6mo after initial diagnosis. Latest relapse that would be considered would be a high-grade recurrence 24mo after initial diagnosis.
* Delayed relapse after adequate BCG: Disease-free after induction and at least one course of maintenance BCG (or second round of induction BCG), but subsequently experience a high-grade recurrence outside of the BCG-unresponsive window (\>6mo for Ta/T1 and \>12mo for CIS). Since a high-grade relapse beyond 24mo after the last dose of BCG would probably respond well to BCG again, this disease state would include only patients with relapse up to 24mo. -
Arm IV: HR BCG unresponsive NMIBC
Patients meeting the definition of BCG-unresponsive disease. Patients with HR NMIBC, "Adequate" induction + maintenance BCG (mBCG): at least 5/6 doses induction, plus at least 2/3 doses maintenance or at least 5/6 doses reinduction
Categories of patients to include in BCG unresponsive arm:
1. \- patients with ≥ T1 HG disease on the first assessment following adequate induction BCG
2. \- patients with ≥ Ta HG disease within 6 months of adequate induction + maintenance BCG
3. \- patients with any component of CIS within 12 months of adequate induction + maintenance BCG
4. \- Any patient previously meeting criteria for BCG unresponsiveness who has a recurrence will be eligible for trial in category of BCG unresponsiveness even if last BCG was more than 1 year ago. -
Arm V: Muscle Invasive Bladder Cancer
Muscle Invasive Cancer who receive ctDNA profiling over time in addition to receiving standard of care, which includes a radical cystectomy. This group includes those who choose adjuvant therapy and those who do not.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Arms I-IV: Overall Mortality at 2 years.
Kaplan-Meier analysis for recurrence-free and progression free survival at 3, 6, 12, 18, 24, and 36 months.
-
Arm V: MIBC patients (Va adjuvant observation and Vb adjuvant therapy)
The primary outcome is to demonstrate the association of ctDNA and disease free state (DFS longitudinally )
Similar trials
Same condition (Non-Muscle Invasive Bladder Neoplasms) and phase, most recent start first.
+43 more trials See the condition page